Clever Leaves Holdings Research and Development Expenses 2019-2023 | CLVR

Clever Leaves Holdings research and development expenses from 2019 to 2023. Research and development expenses can be defined as an expense arising from studies and product development processes.

Clever Leaves Holdings Research and Development Expenses 2019-2023 | CLVR

Clever Leaves Holdings research and development expenses from 2019 to 2023. Research and development expenses can be defined as an expense arising from studies and product development processes.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$80.2B
Zoetis (ZTS)$68.3B
Daiichi Sankyo, - (DSNKY)$47.1B
Takeda Pharmaceutical (TAK)$46.9B
BeOne Medicines - (ONC)$32.3B
Sandoz Group AG (SDZNY)$26.4B
Summit Therapeutics (SMMT)$20.8B
Merck (MKKGY)$17.3B
Shionogi (SGIOY)$14.5B
United Therapeutics (UTHR)$13.8B
Neurocrine Biosciences (NBIX)$13.2B
Orion OYJ (ORINY)$11.7B
IPSEN (IPSEY)$10.9B
Stevanato Group S.p.A (STVN)$7.7B
Corcept Therapeutics (CORT)$7.3B
Madrigal Pharmaceuticals (MDGL)$6.8B
Grifols, S.A (GRFS)$6.8B
Ionis Pharmaceuticals (IONS)$6.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.9B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.4B
Hypermarcas (HYPMY)$3.1B
Crinetics Pharmaceuticals (CRNX)$2.9B
NewAmsterdam Pharma (NAMS)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.6B
Procaps Group, S.A (PROCF)$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.1B
Ocular Therapeutix (OCUL)$1.9B
BioCryst Pharmaceuticals (BCRX)$1.8B